Top Experts Join IsomAb to Advance Blood Flow Treatments for Diabetics

IsomAb Expands Its Clinical Advisory Board

IsomAb Ltd, a biotechnology company from the UK, has announced an exciting development in their team. The company has added numerous leading experts to their Clinical Advisory Board (CAB) to gain top-notch advice on their future clinical trials.

The new CAB members include prominent professionals in vascular surgery and managing diabetic patients with vascular issues. They are expected to provide critical insights for IsomAb's lead program, especially for trials involving diabetic vascular disease.

Leadership Comments on the Expansion

Jackie Turnbull, CEO of IsomAb, shared the importance of this expansion. She emphasized that the new CAB members would bolster their clinical trials by offering their vast expertise. This comes as the company is generating preclinical data for ISM-001, a high-affinity, humanized antibody aimed at improving blood flow in diabetic vascular disease.

Turnbull expressed optimism that these renowned experts would guide IsomAb efficiently through the complex landscape of clinical research, helping to shape robust clinical trials.

Meet the New Advisory Members

The new Clinical Advisory Board consists of:

Prof. Dr. Maarit Venermo – Head of the vascular surgery department at Helsinki University Hospital, focusing on quality in vascular surgical service.

Prof. Dr. med. Sigrid Nikol – Head of Interventional Angiology at St. Georg Hospital, Hamburg, with over three decades of angiogenesis research experience.

Prof. Robert Hinchliffe – Clinical Professor of Vascular Surgery at Bristol Medical School, specializing in diabetes-related complications.

Marc P. Bonaca, M.D., MPH – Cardiologist and Vascular Medicine Specialist at the University of Colorado, focusing on vascular research.

Prof. John C. Lantis – Site Chief and Professor of Surgery at Mount Sinai West Hospital, an authority on limb salvage and wound healing.

Joseph L. Mills, M.D., FACS – Vascular surgeon in Houston, specializing in diabetic foot amputation prevention and limb salvage.

Prof. Michael Edmonds – Consultant Physician at King’s College Hospital, known for his work on diabetic foot care.

Prof. Stephen Bain – Clinical Director of the Diabetes Research Unit at Swansea University, involved in multi-center trials for novel diabetes therapies.

Impact on Future Research

This expansion signifies a substantial step for IsomAb. With this wealth of expertise, the company hopes to push the boundaries of what is possible in treating vascular complications in diabetic patients.

The insights from the new advisory members will be instrumental in designing effective and safe clinical trials for ISM-001, potentially leading to breakthrough therapies.